bevacizumab,panitumumab
roche,takeda,amgen
['paradigm', 'avastin', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm']
paradigm trial: - in ras wt lft-sided mcrc mfolfox6+pani improved os and orr vs mfolfox6+avastin. pfs comparable. - similar result to previous trials.
- anti-egfr seems to be the preferred upfront option in ras wt, braf wt mss mcrc. #asco22 #asco2022 #crcsm 
???????? ?? ??????? - ?????? ???????? Medical Oncologist #breastcancer. MD Anderson Alumni “All tweets are my own and RT?endorsement”